Sarepta Therapeutics Inc (SRPT)

Receivables turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496	380,833	365,135	344,580
Receivables	US$ in thousands	378,806	403,058	318,855	236,808	223,836	217,939	201,509	203,854	178,194	152,990	149,787	127,520	118,203	101,340	121,827	104,028	106,875	90,879	68,032	56,981
Receivables turnover		3.70	3.08	3.47	4.24	4.36	4.28	4.35	4.10	4.30	4.59	4.31	4.71	4.85	5.33	4.06	4.33	3.81	4.19	5.37	6.05

March 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,403,300K ÷ $378,806K
= 3.70

The receivables turnover ratio of Sarepta Therapeutics Inc has fluctuated over the past few quarters. The ratio indicates how efficiently the company is collecting on its accounts receivable. A higher ratio is generally seen as favorable, as it suggests that the company is collecting its outstanding debts more quickly.

Looking at the trend, we see that the receivables turnover ratio has varied between 3.08 and 6.05 over the past 20 quarters. In recent quarters, the ratio has generally been above 4, indicating that Sarepta Therapeutics Inc has been collecting its accounts receivable approximately 4 to 5 times a year.

It is important to note the drop in the ratio from Q4 2021 to Q1 2022, which may indicate a delay in collecting receivables during that period. However, the ratio rebounded in Q2 and Q3 of 2022, reaching levels above 4.30. This improvement could suggest enhanced collection processes or better management of credit terms.

Overall, Sarepta Therapeutics Inc's receivables turnover ratio shows some variability, but the general trend has been relatively stable and within a reasonable range. Further analysis would be needed to understand the specific reasons behind the fluctuations and to assess the effectiveness of the company's accounts receivable management.